^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PIGF inhibitor

    Related drugs:
    12d
    AVT29-GL-C01: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema (2025-522231-34-00)
    P2/3, N=172, Not yet recruiting, Alvotech Swiss AG | N=102 --> 172
    Enrollment change
    |
    Eylea (aflibercept intravitreal)
    22d
    PHOTONiC: A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=333, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    23d
    Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Sam Chun Dang Pharm. Co. Ltd.
    New P2 trial
    |
    Eylea (aflibercept intravitreal)
    28d
    4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=480, Active, not recruiting, 4D Molecular Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    29d
    A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P3, N=356, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    1m
    ALVOEYE-HD: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=256, Not yet recruiting, Alvotech Swiss AG
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    1m
    When the Air Gets Thin, and the Blood Gets Thick: Choroidal Hemangioma in High-Altitude Polycythemia. (PubMed, Cureus)
    The patient also received a single intravitreal Eylea (aflibercept) injection, following which the subretinal fluid subsided significantly...Chronic hypoxia-induced hyperviscosity may contribute to vascular dilation and permeability changes within the choroid. Recognition of this association is crucial for timely diagnosis and effective management of choroidal hemangioma to preserve vision.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    Eylea (aflibercept intravitreal)
    1m
    AVT29-GL-C01: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema (2025-522231-34-00)
    P2/3, N=102, Not yet recruiting, Alvotech Swiss AG
    New P2/3 trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    AVT29-GL-C01: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema (2025-522231-34-00)
    P2/3, N=11, Not yet recruiting, Alvotech Swiss AG
    New P2/3 trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD). (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Insel Gruppe AG, University Hospital Bern
    New trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    AFLIWEST: Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Nantes University Hospital
    New trial • Real-world evidence
    |
    Eylea (aflibercept intravitreal)
    2ms
    4D-150-C004: A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2) (2025-521349-25-00)
    P2/3, N=298, Recruiting, 4d Molecular Therapeutics Inc.
    New P2/3 trial
    |
    Eylea (aflibercept intravitreal)